Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

This was the stock's second consecutive day of gains.

My name is Will Pickering. I cover U.S. Biotech at Bernstein. I am privileged to be joined today by Vertex's CEO, Reshma Kewalramani. And Reshma, welcome. Sure. Sounds good. Well, good morning ...

It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which a week ago released some disappointing quarterly results that could have a notable impact on how ...

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) shares gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings.

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06 ...